As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers. The post Reducing Clinical and Staff Burnout with AI Automation appeared first on MedCity News.
ST. LOUIS — Inside the more than 600 Catholic hospitals across the country, not a single nun can be found occupying a chief executive suite, according to the Catholic Health Association. Nuns founded and led those hospitals in a mission to treat sick and poor people, but some were also shrewd business leaders. Sister Irene…
During cheerleading practice in April, Jana Duey’s sixth grade daughter, Karter, sustained a concussion when she fell several feet headfirst onto a gym floor mat. Days after, Karter still had a headache, dizziness, and sensitivity to light and noise. Karter rested for a week and a half at home in Centennial, Colorado, then returned to…
The physician services firm’s leaders expect to wrap up the sales of most of the company’s office-based practices by the end of the year.
Cost effectiveness analyses (CEA) aim to examine how a new health technologies impact health outcomes and costs over a patient’s lifetime. While extrapolating long-run health benefits and measuring potential cost offsets are important, another important item to estimate is how the cost of the new health technology is likely to evolve over times. This is…
I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases. The post 5 Interesting Companies I Saw at HLTH appeared first on MedCity News.
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The post Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs appeared first…
Maryland has signed an agreement with CMS on the model, which will seek to improve population health and lower costs.
There are some areas where point solutions make a lot of sense, such as when they’re focused on a condition without a lot of comorbidities, according to one healthcare expert. The post Is There Still a Place for Point Solutions? One Investor Weighs In appeared first on MedCity News.
Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing. The post Viking Therapeutics’ Early Clinical Data Continue to…